PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 18, 2024Signal Transduction and Targeted Therapy343 citationsOpen Access

Drug repurposing for cancer therapy

YXYing XiaMSMing SunHHHai Huang

Key Points

Key points are not available for this paper at this time.

Abstract

Cancer, a complex and multifactorial disease, presents a significant challenge to global health. Despite significant advances in surgical, radiotherapeutic and immunological approaches, which have improved cancer treatment outcomes, drug therapy continues to serve as a key therapeutic strategy. However, the clinical efficacy of drug therapy is often constrained by drug resistance and severe toxic side effects, and thus there remains a critical need to develop novel cancer therapeutics. One promising strategy that has received widespread attention in recent years is drug repurposing: the identification of new applications for existing, clinically approved drugs. Drug repurposing possesses several inherent advantages in the context of cancer treatment since repurposed drugs are typically cost-effective, proven to be safe, and can significantly expedite the drug development process due to their already established safety profiles. In light of this, the present review offers a comprehensive overview of the various methods employed in drug repurposing, specifically focusing on the repurposing of drugs to treat cancer. We describe the antitumor properties of candidate drugs, and discuss in detail how they target both the hallmarks of cancer in tumor cells and the surrounding tumor microenvironment. In addition, we examine the innovative strategy of integrating drug repurposing with nanotechnology to enhance topical drug delivery. We also emphasize the critical role that repurposed drugs can play when used as part of a combination therapy regimen. To conclude, we outline the challenges associated with repurposing drugs and consider the future prospects of these repurposed drugs transitioning into clinical application.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Xia et al. (2024) studied this question.

synapsesocial.com/papers/69ff95192ff633f36577994bhttps://doi.org/10.1038/s41392-024-01808-1
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Recent advances in the molecular mechanism of thalidomide teratogenicity2020 · 75 citations
  2. 2Celecoxib could reverse the hypoxia-induced Angiopoietin-2 upregulation in gastric cancer2005 · 18 citations
  3. 3Stabilization of p53 Is Involved in Quercetin-Induced Cell Cycle Arrest and Apoptosis in HepG2 Cells2008 · 135 citations
  4. 4Onco-cardiology: Drug-drug interactions of antineoplastic and cardiovascular drugs2019 · 31 citations
  5. 5EGCG inhibited bladder cancer SW780 cell proliferation and migration both in vitro and in vivo via down-regulation of NF-κB and MMP-92016 · 139 citations